015

15. CPMP. Committee for Proprietary Medicinal Products (CPMP) (2000) “Points to consider on switching between superiority and noninferiority” The European Agency for the Evaluation of Medicinal Products, London. 2000.

014

14. Snappin S. Noninferiority trials. Curr Controll Trials in Cardiovasc Med 2000; 1:19- 21. 2000. DOI: 10.1186/cvm-1-1-019

013

13. Manyando C, Kayentao K, D’Alessandro U, Okafor HU, Juma E, Hamed K. A systematic review of the safety and efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria during pregnancy. Malar J. 2012 May 01;11:141. doi: 10.1186/1475-2875-11-141

012

12. Baiden R, Oduro A, Halidou T, Gyapong M, Sie A, Macete E, et al. Prospective observational study to evaluate the clinical safety of the fixed-dose artemisinin-based combination Eurartesim(R) (dihydroartemisinin/piperaquine), in public health facilities in Burkina Faso, Mozambique, Ghana, and Tanzania. Malar J. 2015 Apr 15;14:160. doi: 10.1186/s12936-015-0664-9.

011

11. D’Alessandro U. Existing antimalarial agents and malaria-treatment strategies. Expert Opin Pharmacother. 2009 Jun;10(8):1291-306. doi: 10.1517/14656560902942319.

009

9. WHO. Methods for surveillance of antimalarial drug efficacy. Geneva, Switzerland. 2009.

010

10. Croft SL, Duparc S, Arbe-Barnes SJ, Craft JC, Shin CS, Fleckenstein L, et al. Review of pyronaridine anti-malarial properties and product characteristics. Malar J. 2012 Aug 09;11:270. doi: 10.1186/1745-6215-15-340.

008

8. Ismail MR, Ordi J, Menendez C, Ventura PJ, Aponte JJ, Kahigwa E, et al. Placental pathology in malaria: a histological, immunohistochemical, and quantitative study. Hum Pathol. 2000 Jan;31(1):85-93. doi: S0046-8177(00)80203-8 [pii]

007

7. Mens PF, Sawa P, van Amsterdam SM, Versteeg I, Omar SA, Schallig HD, et al. A randomized trial to monitor the efficacy and effectiveness by QT-NASBA of artemether- lumefantrine versus dihydroartemisinin-piperaquine for treatment and transmission control of uncomplicated Plasmodium falciparum malaria in western Kenya. Malar J. 2008 Nov 18;7:237. doi: 10.1186/1475-2875-7-237.

005

5. Sagara I, Beavogui AH, Zongo I, Soulama I, Borghini-Fuhrer I, Fofana B, et al. Safety and efficacy of re-treatments with pyronaridine-artesunate in
African patients with malaria: a substudy of the WANECAM randomised trial. Lancet Infect Dis. 2016 Feb;16(2):189-98. doi: 10.1016/S1473-3099(15)00318-7